Camp4 Therapeutics Files 8-K on Shareholder Vote Matters

Ticker: CAMP · Form: 8-K · Filed: Jun 13, 2025 · CIK: 1736730

Sentiment: neutral

Topics: corporate-governance, shareholder-vote, sec-filing

TL;DR

Camp4 Therapeutics held a shareholder vote on June 11th, filing the details today.

AI Summary

Camp4 Therapeutics Corporation filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders on June 11, 2025. The filing details the company's corporate structure, including its incorporation in Delaware and its principal executive offices located at One Kendall Square, Cambridge, MA.

Why It Matters

This filing indicates that Camp4 Therapeutics Corporation held a vote of its security holders, which is a standard corporate governance event that may involve significant decisions for the company.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting a shareholder vote, with no immediate financial or operational risks indicated.

Key Numbers

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders on June 11, 2025?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in the excerpt.

What is the company's primary business or industry?

The company is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its SIC code.

When was Camp4 Therapeutics Corporation incorporated?

The company was incorporated in Delaware.

What is the contact phone number for Camp4 Therapeutics Corporation?

The registrant's telephone number, including area code, is (617) 651-8867.

Is this filing related to any recent significant corporate actions?

This filing is a Current Report on Form 8-K, indicating it reports on events that are considered material to investors, specifically related to a submission to a vote of security holders.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 13, 2025 regarding Camp4 Therapeutics Corp (CAMP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing